Abstract 3972: Comprehensive immune landscape analysis of solid tumors using a 17-Plex immunofluorescence assay in clinical trials
Jaspreet Kaur(Lineage Cell Therapeutics (United States)), Jennifer Bordeaux(Lineage Cell Therapeutics (United States)), Lisa Kattenhorn(American Institutes for Research), Margaret E. McLaughlin(Novartis (Switzerland)), Ying Huang(Boston Biomedical (United States)), Richard Van Krieken(Lineage Cell Therapeutics (United States)), Xun Li(Lineage Cell Therapeutics (United States)), Naveen Dakappagari(Navidea Biopharmaceuticals (United States))
Cited by 0
Related Papers
Restoration of p53 function leads to tumour regression in vivo
|Nature|2007|1.8k
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response
|Nature Medicine|2015|1.4k
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
|Proceedings of the National Academy of Sciences|2013|833
Antibody validation
|BioTechniques|2010|601